Moderna, Inc. (NASDAQ:MRNA) | WebDisclosure

Basculer en Français

8313	Companies
115772	Keywords
55886	Articles
62788	Press releases

Home
Companies
Moderna, Inc.

BRIEF

published on 09/17/2024 at 17:05, 2 months 8 days ago

Moderna reçoit l'approbation de Santé Canada pour la mise à jour de son vaccin contre la COVID-19 ciblant le variant KP.2

Moderne Vaccin Contre Le Covid-19 Santé Canada Spikevax Variante KP.2
BRIEF

published on 09/17/2024 at 17:05, 2 months 8 days ago

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant

COVID-19 Vaccine Health Canada Moderna Spikevax KP.2 Variant
PRESS RELEASE

published on 09/17/2024 at 17:00, 2 months 8 days ago

Moderna reçoit l'approbation de Santé Canada pour le vaccin COVID-19 mis à jour ciblant le variant KP.2 du SRAS-COV-2 pour les personnes âgées de six mois et plus
Moderna Inc. obtient l'autorisation de Santé Canada pour son vaccin SPIKEVAX® mis à jour contre la COVID-19 pour le variant KP.2, renforçant la protection pendant les saisons automne-hiver 2024-2025

COVID-19 Moderna Inc. Santé Canada Vaccin SPIKEVAX®
PRESS RELEASE

published on 09/17/2024 at 17:00, 2 months 8 days ago

Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
Moderna's SPIKEVAX® KP.2 variant COVID-19 vaccine authorized in Canada for 2024-2025 season to protect against COVID-19 strains. Delivery to begin promptly for vaccination campaigns

COVID-19 Vaccine Health Canada Moderna Spikevax Vaccination Campaigns
BRIEF

published on 09/12/2024 at 12:05, 2 months 13 days ago

Moderna R&D Day Highlights Progress and Strategic Priorities

COVID-19 Vaccine Financial Outlook Vaccine Approvals Moderna Updates R&D Strategy
BRIEF

published on 09/12/2024 at 12:05, 2 months 13 days ago

La journée de recherche et développement de Moderna met en lumière les progrès et les priorités stratégiques

Perspectives Financières Vaccin Contre Le Covid-19 Mises À Jour De Moderna Stratégie De R&D Approbations De Vaccins
PRESS RELEASE

published on 09/12/2024 at 12:00, 2 months 13 days ago

Moderna R&D Day Highlights Progress and Strategic Priorities
Moderna, Inc. announces program updates focusing on ten product approvals through 2027, submission of next-gen COVID vaccine and flu/COVID combo vaccine in 2024, positive Phase 3 results for RSV vaccine, and cost efficiency improvements

Moderna Vaccine Phase 3 Results Product Approvals R&D Expense Reduction
BRIEF

published on 09/09/2024 at 13:05, 2 months 16 days ago

Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada

Health Canada Moderna MRNA Vaccines Laval Facility Drug Establishment License
BRIEF

published on 09/09/2024 at 13:05, 2 months 16 days ago

L'usine canadienne de Moderna obtient une licence d'établissement de médicaments de Santé Canada

Vaccins À ARNm Moderne Santé Canada Établissement De Laval Licence D'établissement De Produits Pharmaceutiques
PRESS RELEASE

published on 09/09/2024 at 13:00, 2 months 16 days ago

Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada
Moderna's Laval facility in Canada attains Drug Establishment License, a key step towards onshore mRNA vaccine production by 2025. This milestone boosts national vaccine supply

Canada Manufacturing Facility Moderna MRNA Vaccines Drug Establishment License

Accesswire

Published on 11/26/2024 at 00:37, 3 minutes ago

CORRECTION; CoTec Holdings Corp. Announces Convertible Loan Agreement
Published on 11/26/2024 at 00:20, 20 minutes ago

NexgenRx Announces Third Quarter Results and Declaration of Divdend
Published on 11/26/2024 at 00:00, 40 minutes ago

Medicure Reports Financial Results For Quarter Ended September 30, 2024
Published on 11/26/2024 at 00:00, 40 minutes ago

Justera Health Revises Vesting Schedule of RSU Grant
Published on 11/25/2024 at 23:20, 1 hour 20 minutes ago

Empyrean Therapeutics Acquires TLR-2 Antagonist Molecule From Eos Therapies to Advance and Commercialize Breakthrough Cancer Treatment

View all ACCESSWIRE

EQS Group

Published on 11/25/2024 at 20:35, 4 hours 5 minutes ago

Launch of World Advanced Manufacturing & Logistics Expo & Summit (WAM Morocco) 2025 to Advance the Country’s Shift Towards Next-Generation Industries and High-Value Manufacturing
Published on 11/25/2024 at 20:35, 4 hours 5 minutes ago

World Advanced Manufacturing & Logistics Expo & Summit (WAM Morocco) 2025 : Le Maroc se positionne comme leader des industries de nouvelle génération
Published on 11/25/2024 at 20:34, 4 hours 5 minutes ago

Avolta wins new ten-year contract, adds Manaus Airport to Brazil portfolio
Published on 11/25/2024 at 19:00, 5 hours 40 minutes ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 18 NOVEMBRE 2024 au 22 NOVEMBRE 2024
Published on 11/25/2024 at 18:55, 5 hours 45 minutes ago

Molten Ventures Plc: HOL-Holding(s) in Company

Les Echos

Published on 11/25/2024 at 18:00, 6 hours 40 minutes ago

Chiffre d’affaires consolidé 2023-2024 : 91 M€ en repli de 9,4 %
Published on 11/25/2024 at 17:55, 6 hours 45 minutes ago

Déclaration des transactions sur actions propres réalisées du 18/11/2024 au 22/11/2024
Published on 11/25/2024 at 17:55, 6 hours 45 minutes ago

Disclosure of trading in own shares from 18/11/2024 to 22/11/2024
Published on 11/25/2024 at 17:45, 6 hours 54 minutes ago

Reporting on share buyback transactions carried out between November 19 and November 22, 2024
Published on 11/25/2024 at 17:45, 6 hours 54 minutes ago

Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 19 et le 22 novembre 2024

View all LES ECHOS COMFI WIRE